Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Net Income (2020 - 2025)

Mirum Pharmaceuticals has reported Net Income over the past 6 years, most recently at -$5.7 million for Q4 2025.

  • Quarterly results put Net Income at -$5.7 million for Q4 2025, up 75.91% from a year ago — trailing twelve months through Dec 2025 was -$23.4 million (up 73.43% YoY), and the annual figure for FY2025 was -$23.4 million, up 73.43%.
  • Net Income for Q4 2025 was -$5.7 million at Mirum Pharmaceuticals, down from $2.9 million in the prior quarter.
  • Over the last five years, Net Income for MIRM hit a ceiling of $57.3 million in Q4 2021 and a floor of -$74.0 million in Q2 2023.
  • Median Net Income over the past 5 years was -$26.1 million (2022), compared with a mean of -$24.7 million.
  • Biggest five-year swings in Net Income: soared 253.97% in 2021 and later tumbled 175.01% in 2023.
  • Mirum Pharmaceuticals' Net Income stood at $57.3 million in 2021, then crashed by 163.6% to -$36.4 million in 2022, then rose by 2.12% to -$35.7 million in 2023, then soared by 33.28% to -$23.8 million in 2024, then skyrocketed by 75.91% to -$5.7 million in 2025.
  • The last three reported values for Net Income were -$5.7 million (Q4 2025), $2.9 million (Q3 2025), and -$5.9 million (Q2 2025) per Business Quant data.